茯苓多糖联合恩诺沙星体内外抗菌活性评价

Antibacterial Activity Evaluation of Pachymaran Combined with Enrofloxacin in vivo and vitro

通过体内外抑菌试验考察茯苓多糖和恩诺沙星联合抗菌的生物活性。采用二倍稀释法测定茯苓多糖联合恩诺沙星对浮游菌的最小抑菌浓度(Minimal Inhibitory Concentration,MIC),MTT法检测茯苓多糖联合恩诺沙星对细菌生物膜(bacterial biofilm,BBF)的抑制作用,同时腹腔注射SA建立小鼠腹腔感染模型,并在此基础上,通过腹腔给药的方式,检测茯苓多糖联合恩诺沙星在体内抑制SA的效果。在体外抑制浮游菌的试验中,茯苓多糖联合恩诺沙星对鸡BSA的MIC为16μg/mL(以恩诺沙星计);茯苓多糖联合恩诺沙星对SA的MIC为8μg/mL(以恩诺沙星计);茯苓多糖联合恩诺沙星对E.coli的MIC为4μg/mL(以恩诺沙星计);在体外抑制细菌生物膜的试验中,茯苓多糖可以改善恩诺沙星清除细菌生物膜的能力;在治疗小鼠腹腔感染试验中,茯苓多糖可以使恩诺沙星抑制SA的活性增强。结果表明,茯苓多糖具有增强恩诺沙星抗菌能力的作用,有效减少恩诺沙星的使用剂量。

In vivo and in vitro combined medicine sensitivity test was used to detect the antibacterial activity of pachymaran and enrofloxacin.The minimum inhibitory concentration for pachymaran and enrofloxacin and their joint action against floating bacteria in vitro were determined by double dilution method.According to the results of MIC,the inhibitory effect of pachymaran combined with enrofloxacin on bacterial biofilm was detected by MTT method.At the same time,the model of abdominal infection in mice was established by intraperitoneal injection of SA.On this basis,the inhibition effect of pachymaran combined with enrofloxacin on SA in vivo was detected by intraperitoneal administration.In vitro experiment of inhibiting BSA floating bacteria,the MIC of pachymaran combined with enrofloxacin was 16μg/mL(measured by enrofloxacin);In vitro experiment of inhibiting SA floating bacteria,the MIC of pachymaran combined with enrofloxacin was 8μg/mL(measured by enrofloxacin);In vitro experiment of inhibiting E.coli floating bacteria,the MIC of pachymaran combined with enrofloxacin was 4μg/mL(measured by enrofloxacin);In vitro experiment of inhibiting BBF,pachymaran could improve the ability of removing BBF by enrofloxacin.In the treatment of abdominal infection in mice,pachymaran increased the activity of enoxacin in inhibiting SA.The results showed that pachymaran could enhance the antibacterial ability of enrofloxacin and effectively reduce the dosage of enrofloxacin.